T-Cell Lymphoma
The latest news, research, and perspectives in T-cell lymphoma. Most T-cell lymphomas are non-Hodgkin lymphomas that develop from mature T cells. The most common subtypes include mycosis fungoides, anaplastic large-cell lymphoma, and precursor T-lymphoblastic lymphoma.
Advertisement
Denileukin diftitox is an IL-2-based immunotherapy for patients with relapsed or refractory CTCL.
The US FDA has lifted the partial clinical hold on lacutamab following its analysis of a mortality in the TELLOMAK trial.
Enrollment paused in lacutamab cutaneous and peripheral T-cell lymphoma trials after unexpected severe adverse reaction.
Swaminathan Iyer, MD, joins Chadi Nabhan, MD, MBA, FACP, to discuss advances in T-cell lymphoma.
Dr. Horwitz and the hosts focus on the three most common types of PTCL and the latest research.
A first-in-human phase I trial will evaluate escalating doses of BITT2101 in patients with non-Hodgkin lymphoma.
Advertisement
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
The regimen is under further evaluation in a randomized trial.
The proposed second phase III study comes in the wake of the recently published phase III FLASH trial.
The approval of the treatment provides patients with an alternative to a product that has historically been in shortage.
A new transcriptomic approach to the molecular classification of PTCL subtypes may have potential as a diagnostic tool.
A Biologics License Application was submitted to the FDA by the manufacturer of the drug denileukin diftitox.
The use of extracorporeal photopheresis declined in patients with Sézary syndrome as the COVID-19 pandemic began.
The number of cases of cutaneous T-cell lymphoma continues to increase in the United States.
There is a knowledge gap about subcutaneous panniculitis-like TCL owing to its rarity and diagnostic difficulty.
Updated staging and clinical trial guidelines for primary cutaneous lymphomas (PCLs) have been proposed.
Dr. Pro discusses the exciting advancements made in lymphoma and what still needs to be done to improve patient outcomes.
SGX301 is a novel, first-in-class, photodynamic therapy utilizing visible light for activation.
The single-center trial included adults with R/R multiple myeloma, T-cell lymphoma, or acute myeloid leukemia.
A pegasparaginase-based chemotherapy regimen showed promising preliminary results when compared to a regimen that was ...
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.